Altitude Life Science Ventures
QuietFiled to raiseKirkland, WAPharmaceuticals, BiotechnologyLast fund filed 2020
1 on a current fund
last 24 months
across filed funds
| Vehicle | Filed | Target | Sold to date | Investors |
|---|---|---|---|---|
| Altitude Life Science Ventures Fund IVFiled to raise in 2020, with no closing reported yet. | 2020 | $150M | $0 | 0 |
| Altitude Life Science Ventures Side Fund III | 2019 | $50M | $50M | 1 |
| ALTITUDE LIFE SCIENCE VENTURES FUND IIIFiled to raise in 2018, with no closing reported yet. | 2018 | $125M | $0 | 0 |
| Altitude Life Science Ventures Side Fund II | June 2015 | $90M | $90M | 1 |
Amounts are Item 13 as filed: the target is the whole offering, and the amount sold is cumulative across amendments rather than a final close. The filing carries no per-investor amount, so a firm’s own cheque is not recoverable here.
1 partner is named across this firm’s filings, 1 of them on a fund it is deploying now.
| Partner | Activity | Categories | Board seats | Last 24mo |
|---|---|---|---|---|
| David Maki | Quiet | Biotech & pharma | 3 | 0 |
Classified sectors of Altitude Life Science Ventures’s own portfolio companies, based on 3 with a verified or cited source.
Not a filing value: this is Lev’s own classification of each company, one company one vote regardless of how many of Altitude Life Science Ventures’s partners are named on its board, shown only when we found a specific, checkable source. Companies with no source read as unclassified and are left out of the shares above.
| Firm | Shared boards | Companies |
|---|---|---|
| ARCH Venture Partners | 2 | Pulmatrix Operating Company, Pulmatrix |
| Polaris Partners | 2 | Pulmatrix Operating Company, Pulmatrix |
| Abingworth Bioventures | 1 | EFFECTOR THERAPEUTICS |
| Sofinnova Venture Partners |
| Altitude Life Science Ventures Fund IIFiled to raise in 2015, with no closing reported yet. | 2015 | $75M | $0 | 0 |
Activity is filed board seats in the last 24 months: 4+ Active, 2–3 Selective, 1 Slowing, none Quiet. A firm's tier totals its partners, so an active firm may be four partners with one seat each. It undercounts partners who invest without taking a board seat, and filings lag a closing by weeks, so Quiet means the paperwork is quiet, not the person.
| 1 |
| EFFECTOR THERAPEUTICS |
| The Column Group | 1 | EFFECTOR THERAPEUTICS |
| U.S Venture Partners | 1 | EFFECTOR THERAPEUTICS |
A shared board seat: a company where filings name a Altitude Life Science Ventures partner and a partner at the other firm, both with a clean identity match. Not a claim either firm led or co-led the round, only that both are named on the same board.